Effect of Anagliptin and Sitagliptin on Low-density Lipoprotein Cholesterol in Patients With Type 2 Diabetes and Cardiovascular Risk Factors: Randomized Controlled Trial
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 15 Mar 2018
At a glance
- Drugs Anagliptin (Primary) ; Sitagliptin (Primary)
- Indications Coronary artery disease; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms REASON
- 10 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 26 May 2016 Planned End Date changed from 1 Mar 2018 to 1 Dec 2018.